Liver Diseases  >>  Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax
NCT00511095: Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

Completed
2
207
US
HEPLISAV
Dynavax Technologies Corporation
Hepatitis B
10/07
03/08
NCT00498212: A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

Terminated
2
41
Canada
1018 ISS-HBsAg-Single, HEPLISAV™, 1018 ISS-HBsAg-Double
Dynavax Technologies Corporation
Hepatitis B
08/08
10/08

Download Options